By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Next-generation sequencing technology firm GnuBio has completed its Series A equity financing round raising $8 million, which the company will use to accelerate the beta program for its platform.

The round had 12 participants, though company CEO John Boyce declined to identify them. GnuBio raised the first $3 million of the round in November and raised the remaining $5 million upon hitting certain milestones, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.